L3MBTL histone methyl-lysine binding protein 1 (L3MBTL1)

L3MBTL histone methyl-lysine binding protein 1 (L3MBTL1) is a member of the polycomb group (PcG) of proteins that acts as a "chromatin reader" by binding mono- and dimethylated lysine residues on histones (primarily H4K20 and H1bK26), as well as non-histone targets such as p53 and RB1. Through its MBT domains, L3MBTL1 compacts chromatin and represses gene transcription. It can influence key cellular processes including cell cycle progression, senescence, and genomic stability. Its activity is context- and cell type-dependent, and loss or dysregulation has been implicated in a range of disorders including cancer, neurodegeneration, and immunodeficiency. Experimental inhibitors such as UNC669 are being explored for their ability to modulate these processes, but clinical use remains limited to preclinical studies.

Other names

Lethal(3)malignant brain tumor-like protein 1L3MBTL1KIAA0681L3MBTLL(3)mbt protein homologZC2HC3DJ138B7.3Lethal (3) malignant brain tumor L(3)Histone methyl-lysine binding protein

Inhibition of L3MBTL1 prevents chromatin compaction, leading to transcriptional derepression by blocking methyl-lysine binding. This may activate p53, enhance proteasomal protein clearance, and potentially be neuroprotective in preclinical models.